Home > Healthcare & Medical Devices > Allergic Rhinitis Drugs Market

Allergic Rhinitis Drugs Market Size By Disease (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis), By Treatment (Antihistamines, Immunotherapy {SCIT, SLIT}, Corticosteroids, Decongestants), By Drug (Prescription, OTC), By Route of Administration (Oral, Nasal, Intraocular, Intravenous), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Channel), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI5413
  • Published Date: Jan 2023
  • Report Format: PDF

Industry Statistics

Allergic Rhinitis Drugs Market size was recorded at over USD 12 billion in 2022. Driven by consistent innovations in allergic rhinitis drugs, the industry is estimated to grow at more than 2.5% CAGR from 2023 to 2032.
 

The increasing prevalence of allergic rhinitis is expected to fuel market growth. Several epidemiological studies have shown that the disease burden caused by allergies has significantly increased in the past few years. Moreover, air quality deterioration in developed nations due to cumulative industrial practices has escalated the number of allergic rhinitis cases, which is speculated to bolster product penetration.
 

Allergic Rhinitis Drugs Market

Get more details on this report - Request Free Sample PDF
 

Furthermore, technological advancements in the field of allergy diagnosis and treatment are also forecast to positively influence business dynamics. The considerable surge in deploying technologically advanced methods, tools, and mechanisms by authorities and organizations globally has uplifted product adoption.
 

Side effects of these drugs may restrain allergic rhinitis drugs market progression

Side effects associated with allergic rhinitis treatments are a major factor restraining market growth. The most frequent side effects of treating allergic rhinitis are nosebleeds, excruciating migraines, eye and nose discomfort, urinary flow in males, and boost blood pressure in hypertensive patients. Altogether, the growing practice of self-medication without a doctor's prescription leads to difficulties. Nonetheless, mounting healthcare spending and the availability of highly potent drugs are likely to aid market players in overcoming this issue.
 

Increasing prevalence of breathing-related disorders to accelerate segment trends

Global Allergic Rhinitis Drugs Market Share by Disease Type

Get more details on this report - Request Free Sample PDF
 

Based on disease, the industry is split into seasonal allergic rhinitis, occupational allergic rhinitis, and perennial allergic rhinitis. The seasonal allergic rhinitis segment accounted for more than 42% of the allergic rhinitis drugs market share in 2022 and is further slated to witness robust growth in the coming years. The rise in breathing-related illnesses caused by outdoor allergens including weed and grass pollen is proliferating product uptake. As per the Asthma and Allergy Foundation of America, grass pollen affects around 10 to 30% of children and adults in the United States.
 

Wide variety of drugs inclusion to help prescription drugs gain traction

Global Allergic Rhinitis Drugs Market Share, By Drug, 2022 (%)

Segment

Global market share (%), 2022

Prescription 57.60%
OTC 42.40%

Get more details on this report - Request Free Sample PDF
 

The allergic rhinitis drugs market is categorized in terms of drug into prescription and OTC. The prescription segment is speculated to account for a valuation of over USD 8.5 billion by 2032. The strong inclination of allergic patients experiencing a runny nose, itchy eyes, postnasal drip, and other symptoms toward prescription drugs is primarily accelerating segment share. The segment growth is also driven by the inclusion of a wide range of allergic drugs from several categories, including corticosteroids, antihistamines, and leukotriene receptor antagonists, among others, under the prescribed drug segment.
 

Ability to boost immunity strength to push immunotherapy demand

With respect to treatment, the allergic rhinitis drugs market is divided into antihistamines, corticosteroids, immunotherapy, decongestants, and others. The immunotherapy segment is poised to depict over 3% CAGR from 2023 to 2032. By using this technique, the body's immune system builds up an immunity to tolerate allergens and doesn't react to active allergens. As a result of its effectiveness on SAR patients, immunotherapy is considered the only disease-modifying therapy for allergic rhinitis. In addition, providers increase allergens in every shot, escalating immunity in the body.
 

High convenience to accelerate oral route of administration

Based on the route of administration, the industry is classified into oral, intraocular, nasal, and intravenous. The allergic rhinitis drugs market size from the oral segment is anticipated to garner more than USD 6.5 billion in revenue by 2032. The clinical advantages associated with the oral route of administration, such as its high level of convenience, low cost, and non-invasive approach, are encouraging segment uptake. Tablets, capsules, and solutions, among other formulations, are used to administer the oral dose.
 

Positive inclination of elderly patients toward online channel to define the industry landscape

In terms of distribution channel, the allergic rhinitis drugs market is separated into hospital pharmacies, retail pharmacies, and online channel. The online channel segment valuation is foreseen to reach over USD 4 billion by 2032. The rising use of online portals and e-commerce platforms for ordering and delivering prescription drugs at the convenience of patients is set to foster segment growth. Moreover, the availability of swift service, beneficial discounts & offers from various manufacturers, and the strong preference of elderly patients are driving the segment growth.
 

Increasing healthcare expenditure to aid North America emerge as a prominent revenue pocket

Global Allergic Rhinitis Market By Region

Get more details on this report - Request Free Sample PDF
 

In the regional context, the allergic rhinitis drugs market is segmented into Europe, Asia Pacific, North America, the Middle East & Africa, and Latin America. The North America market registered more than 37% revenue share in 2022. Soaring technological developments in treatment methods such as corticosteroid drugs are fueling business outlook. For instance, in March 2022, US FDA approved Rx-to-OTC for Nasonex by Perrigo. Moreover, the positive focus of industry players on OTC product portfolio and rising healthcare expenditures are accelerating regional market expansion.
 

Product innovation to improve the allergic rhinitis drugs industry outlook

Merck & Co., GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Unichem Laboratories, Stallergenes Greer, Sanofi S.A., Alcon (Novartis AG), Johnson & Johnson, Meda AB, Mylan NV, Allergy Therapeutics PLC, ALK-Abelló A/S, Glenmark Pharmaceuticals Ltd, Bayer AG, Dr. Reddy’s Laboratories, Adamis Pharmaceuticals, and Sun Pharmaceuticals are key participants involved in the market. These firms focus on thorough R&D programs to expand their product portfolio and propel their market position.
 

Impact of COVID-19 on the allergic rhinitis drugs market trends

The recent outbreak of COVID-19 had a negative impact on the allergic rhinitis drugs industry as a result of dynamic trends in demand, supply shortages, panic buying & stocking, regulation changes, and R&D process changes that impacted the market revenue. However, recently, the market observed a rapid recovery in line with new strategies undertaken by government agencies to manage AR patient burden as well as COVID-19 cases. For instance, the European Academy of Allergy and Clinical Immunology (EAACI), along with the ARIA-MASK study group, suggested the use of intranasal steroids for the treatment of allergic rhinitis, which has been lucrative for business growth.
 

The allergic rhinitis drugs market report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments:

By Disease

  • Seasonal Allergic Rhinitis
  • Perennial Allergic Rhinitis
  • Occupational Allergic Rhinitis

By Treatment

  • Antihistamines
  • Immunotherapy
    • SCIT
    • SLIT
  • Corticosteroids
  • Decongestants
  • Others

By Drug

  • Prescription
  • OTC

By Route of Administration

  • Oral
  • Nasal
  • Intraocular
  • Intravenous

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Channel

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea 
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • MEA

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market for allergic rhinitis drugs was valued at more than USD 12 billion in 2022 and is set to progress at over 2.5% CAGR over the next 10 years owing to technological advancements in the field of allergy diagnosis and treatment.

Online channel segment is foreseen to reach over USD 4 billion by the end of 2032 on account of the availability of swift service, beneficial discounts & offers from various manufacturers, and the strong preference of elderly patients.

Oral segment is poised to garner more than USD 6.5 billion in revenue by 2032 as a result of its high level of convenience, low cost, and non-invasive approach.

Allergic rhinitis drugs market in North America accounted for more than 37% of the revenue share in 2022 due to soaring technological developments in treatment methods and rising healthcare expenditures in the region.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 18
  • Tables & Figures: 351
  • Countries covered: 18
  • Pages: 220

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount